Autologous Peripheral Blood Mononuclear Cell Implantation for Patients With Peripheral Arterial Disease Improves Limb Ischemia

Clinical Laboratories, University of the Ryukyus, Okinawa, Okinawa, Japan
Circulation Journal (Impact Factor: 3.94). 11/2005; 69(10):1260-5. DOI: 10.1253/circj.69.1260
Source: PubMed


Implantation of bone marrow mononuclear cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous peripheral blood mononuclear cells (PBMNCs) implantation after granulocyte-colony stimulating factor (G-CSF)-induced mobilization was investigated in patients with severe peripheral arterial disease.
Six cases were enrolled: 5 of thromboangitis obliterans and 1 of arteriosclerosis obliterans. Following administration of G-CSF (10 microg . kg(-1) . day(-1)), PBMNCs were harvested and injected intramuscularly (5 legs and 1 arm) for 2 days for the patients with ischemia of the legs. No serious adverse events related to G-CSF administration, harvest or implantation were observed during this study period. Improvement in the ankle - brachial pressure index (ABI: >0.1) was seen in 4 patients at 4 weeks and ischemic ulcers improved in 3 of 3 patients. The mean maximum walking distance significantly increased from 203 m to 559 m (p=0.031) at 4 weeks and was sustained for 24 weeks. Significant improvement was seen in physiological functioning subscale of Short Form-36.
Implantation of PBMNCs collected after G-CSF administration could be an alternative to therapeutic angioplasty in patients with severe peripheral arterial disease.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell therapy is an emerging field whose technology is being investigated for the treatment of a variety of injuries and diseases affecting multiple tissue types. Many questions exist in the field of cell therapy, from understanding the basic mechanisms of action, to the optimal methods for preparing and administering cells to the patient. Answers to these questions will help determine the best cell source, optimal protocols for ex vivo manipulation of cells, and the best methods for delivery of cells. This chapter details one experience in the development of an ex vivo cultured autologous cell therapy for tissue repair, in this case the healing of non-union bone fractures. Methods were developed to expand a population of bone marrow mononuclear cells in culture resulting in a mixed population of cells with greatly enhanced bone-forming potential. These Tissue Repair Cells (TRCs) have been shown to possess multi-lineage potential both in vitro and in vivo in animal models. A manufacturing platform has been designed to culture and harvest the cell product in an automated closed fashion. After mixing TRCs with a bone scaffold material, cells maintained their ability to proliferate, secrete cytokines, and differentiate into the desired cell lineage. Preliminary results have demonstrated that TRCs can be successfully implanted and heal bone fractures in the clinic.
    01/1970: pages 251-274;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Converging evidence indicates that peripheral blood (PB) contains stem cells (SCs) with multidifferentiation potential, thus representing a potential source for regenerative medicine in several human disorders, as has also been confirmed by promising results obtained in several preliminary clinical trials. In addition to the classic haematopoietic SCs, PB also harbours endothelial progenitor cells, mesenchymal SCs, tissue-committed SCs and monocyte-like SCs. In spite of a series of different names and/or definitions, a large overlap seems to exist among surface markers, functions and origin of these different SC types. This review analyses the different subsets of SCs described in PB, the different hypotheses suggested to explain their origin, and the possible mechanisms that provide the basis for their biological potential.
    Expert opinion on biological therapy 04/2006; 6(3):193-202. DOI:10.1517/14712598.6.3.193 · 3.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recently, clinical studies have shown that novel therapies, including cell implantation and transfer of gene encoding for angiogenic growth factors, are effective in patients with critical limb ischemia who have no other treatment option. This concept is called therapeutic angiogenesis. Cell therapy involves implantation of bone-marrow or peripheral mononuclear cells and endothelial progenitor cells (CD34(+) cells) in the gastrocnemius of the ischemic leg. Gene therapy involves delivery of vascular endothelial growth factor and fibroblast growth factor using a plasmid or adenoviral vector. Critical limb ischemia is associated with endothelial dysfunction as well as excess oxidative stress. A balance of oxidative stress and nitric oxide play an important role in the development of atherosclerosis in patients with peripheral arterial diseases. It has been reported that both cell therapy and gene therapy improve endothelial function in the resistant artery of an ischemic limb. Cell therapy or gene therapy in combination with pharmacological therapy as an antioxidant could be useful for restoration of endothelial function and prevention of development of atherosclerosis in patients with critical limb ischemia. In this review, we discuss the relationships between oxidative stress, endothelial function, and angiogenesis and the mechanism by which therapeutic angiogenesis improves endothelial function.
    Current Pharmaceutical Biotechnology 05/2006; 7(2):109-16. DOI:10.2174/138920106776597658 · 2.51 Impact Factor
Show more